Having Surgery? Donate fresh live tumor for researchers!
$1 MILLION INTERNATIONAL COLLABORATIVE PROJECT TO START
8/8/16 The Liddy Shriver Initiative visualized and coordinated a comprehensive LMS study by Drs. Fletcher, van de Rijn, Chibon, Bauer and Langenau. This study is funded by the Liddy Shriver Initiative ($250,000), LMSarcoma Direct Research Foundation ($125,000,) National LMS Foundation ($125,000) and from the researchers’ own resources ($500,000.) They plan to sequence the whole genome of 200 LMS tumors, investigate the PI3K-AKT-mTOR pathway and test new therapies with cell lines, mice and zebra fish. The ultimate goal is to test these in clinical trials. Details of the study
Phase II Tivozanib Results
Out of 48 heavily pretreated soft tissue sarcoma participants, 27 had LMS. Here are the responses of the 27 LMS patients at 16 weeks:
- 1 had partial response;
- 14 had stable disease
- 12 had progressive disease
Looking for new options? Have your doctor order this free test to see if you have this gene rearrangement which might respond to the new drug Entrectinib by Ignyta.
Olaratumab + Doxorubicin Extends Survival
10/19/2016 The FDA has approved olaratumab (Lartruvo) for soft-tissue sarcoma when used with doxorubicin (Adriamycin) as first-line treatment. This is the first “first-line” treatment approved for sarcoma in 40 years.
LMS Blood Drive Update
The LMS blood drive has been a success; over 167 samples have been collected for the circulating DNA research project. The project is spearheaded by Dr. Kristen Ganjoo and Dr. Matt van de Rijn of Stanford University, whose objective is to identify whether a treatment is working or not by looking for tumor DNA in the patient’s blood. This could potentially help patients long before they get their next CT scan. The second goal of the project is to determine if a uterine fibroid is a leiomyosarcoma tumor. Thank you, to all LMS blood donors!
Biomarker Trabectedin Response
Dr. Suzanne George (Dana Farber) and Dr. Matt van de Rijn (Stanford) are trying to identify a biomarker which will predict who will respond to Trabectedin (yondellis.)
(means to give life, heal, cure)
LMSdr RETREAT in Kihei, Maui, Hawaii
Join us for a day in Kihei of healing workshops & dinner with sarcoma experts. Group activities for the rest of the week will be available including a luau, paint & sip party, snorkeling, hula lessons and more!
10am – 10pm
$50 per person (includes lunch & dinner)
NEW T-Shirts Order on Amazon Smile and receive free shipping with Amazon Prime
The LMS Facebook Group raised $10,465 in February for the Show Your Love Campaign!
Make a donation to LMSdr and receive the 2016 LMS Conference VIDEO as our thank you gift. (Suggested donation $50 or more.)
Lemonade Stand for LMS
These children raised and donated $100 in honor of their grandmother, Bernadette Hollis.
RARE Foundation Alliance
LMSdr is now a member of the RARE Foundation Alliance and attended the RARE Patient Advocacy Summit September 22-23, 2016.
High School Fundraiser
Student Billy Woltz and his band raised $4,453.00 with a benefit concert in honor of their Logan High School teacher Kelley Schaefer Hoellrich in Ohio. Congrats to an awesome group of teens!
LMSdr has been a supporter of the Congress’s 21st Century Cures Initiative and its companion legislation in the Senate. H.R.5052, known as the OPEN ACT, is a bipartisan legislation that could double the number of treatments available to rare disease patients, has not yet been passed by Congress. We are urging advocates to contact their representatives in the House and the Senate to ask that they step-up for rare disease patients and co-sponsor the OPEN ACT.
We are thrilled to announce that Ofir Gabay has joined our board as Treasurer. Ofir is an accounting professional and independent business owner. He lost his mother to LMS in 2015 and wants to help our cause. Welcome, Ofir!
Shop & Donate
Thank you for shopping at Amazon Smile and designating a percentage of the profit to LMSdr. You raised $430 within the last six months! New users can register at Smile.Amazon.com